Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 07/30/21
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic RhinosinusitisBusiness Wire • 07/26/21
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt FundingBenzinga • 07/23/21
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term LoanBusiness Wire • 07/22/21
Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?Zacks Investment Research • 06/29/21
Why Is Intersect ENT (XENT) Down 10.8% Since Last Earnings Report?Zacks Investment Research • 06/09/21
Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus SurgeryBusiness Wire • 05/20/21
Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
Intersect ENT Announces Date Change for First Quarter 2021 Financial Results AnnouncementBusiness Wire • 04/29/21
EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus DilationBusiness Wire • 04/29/21
Intersect ENT (XENT) Down 5.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 04/08/21